Glioblastoma, Adult Clinical Trial
Official title:
A Study to Evaluate the Safety and the Efficacy of Transient Opening of the Blood-brain Barrier (BBB) by Low Intensity Pulsed Ultrasound With the SonoCloud-9 Implantable Device in Recurrent Glioblastoma Patients Eligible for Surgery and for Carboplatin Chemotherapy
Recurrent glioblastoma (GBM) is a disease with high unmet clinical need. The standard of care for patients with GBM includes surgery, radiotherapy and chemotherapy. Despite this aggressive treatment, the overall median survival of patients with GBM remains at 15-20 months. In more than 95% of cases, tumor recurrence is observed within 2 cm to 3 cm of the resection cavity within 4-7 months after initial treatments. One of the main causes of recurrence is the inability of chemotherapies to enter the brain from the systemic circulation due to the blood-brain barrier (BBB). The BBB is unique to cerebral blood vessels and blocks most drugs from entering the brain in sufficient concentrations. The SonoCloud-9 (SC9) System delivers ultrasound to locally and transiently increase the permeability of the BBB to allow the passage of drugs into the cerebral parenchyma. The SC9 is dimensioned to cover the resection area and surrounding tissues in patients with recurrent GBM. The large sonicated volume covered by the SC9 device allows for broad BBB disruption and should allow for carboplatin chemotherapy to penetrate the surrounding tumor infiltrative area. By enhancing drug concentrations, it is hypothesized that further disease progression will be prevented.
This will be an open-label, Phase 1/2a, multicenter, single-arm, interventional trial that will first evaluate the dose limiting toxicity (DLT) of escalating numbers of ultrasound beams at constant acoustic pressure using a standard escalation (Phase 1) and then confirm the safety and efficacy of BBB opening (Phase 2a expansion). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03291977 -
Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)
|
Phase 3 | |
| Active, not recruiting |
NCT03665545 -
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT03714334 -
DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma
|
Phase 1 | |
| Recruiting |
NCT03277638 -
Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)
|
Phase 1/Phase 2 | |
| Completed |
NCT03158389 -
NCT Neuro Master Match - N²M² (NOA-20)
|
Phase 1/Phase 2 | |
| Completed |
NCT03522298 -
Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
|
Phase 2 | |
| Recruiting |
NCT03213002 -
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
|
Phase 1/Phase 2 | |
| Completed |
NCT03232424 -
NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
|
Phase 1 | |
| Active, not recruiting |
NCT04116658 -
First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03618667 -
GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification
|
Phase 2 | |
| Recruiting |
NCT04128774 -
Function and Composition of Regulatory B Cells in Participants With Glioblastoma
|
||
| Completed |
NCT04610229 -
Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas.
|
N/A | |
| Active, not recruiting |
NCT02974738 -
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
|
Phase 1 | |
| Recruiting |
NCT03025893 -
A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT03181477 -
Study Evaluating the Efficacy of Radiotherapy With SIB-IMRT, Associated With Temozolomide in Glioblastomas
|
N/A | |
| Completed |
NCT03075514 -
Ketogenic Diets as an Adjuvant Therapy in Glioblastoma
|
N/A |